Adverse Health Outcomes of Psilocybin, LSD, MDMA, Ibogaine, and 5-MeO-DMT
Otto Simonsson, Melissa Bradley, Joshua Curtis Black, Karilynn M Rockhill, Andrew A. Monte, Peter S. Hendricks
JAMA Network Open September 29, 2026 DOI: 10.1001/jamanetworkopen.2026.36756 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Cross-sectional survey Peer reviewed |
|---|---|
| Population | Nationally representative sample of US adults |
| Interventions | Psilocybin Lysergic acid diethylamide (LSD) 3 4-methylenedioxymethamphetamine (MDMA) Ibogaine 5-methoxy-N N-dimethyltryptamine (5-MeO-DMT) |
| Topics | 5-MeO-DMT DMT Ibogaine LSD MDMA Psilocybin |
| Key findings | The work describes self-reported health outcomes attributed to recent use of psilocybin, LSD, MDMA, ibogaine, and 5-MeO-DMT in a nationally representative survey of US adults. No specific outcomes, comparisons, or effect sizes are reported in the available text. |
Abstract
This cross-sectional study describes health outcomes attributed to recent use of psilocybin, lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA), ibogaine, and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a nationally representative survey of US adults.
In the evidence
This study is part of the evidence base for 4 syntheses in the library. Here is how each one recorded it.
-
State of the evidence: 5-MeO-DMT Unclear
Describes self-reported health outcomes attributed to recent use of several psychedelics including 5-MeO-DMT, without specific outcomes or effect sizes reported in the available text.
Synthesized
-
State of the evidence: DMT Unclear
Describes self-reported health outcomes attributed to recent use of psilocybin, LSD, MDMA, ibogaine, and 5-MeO-DMT, but no specific outcomes or effect sizes are reported in the available text.
Synthesized
-
State of the evidence: LSD Unclear
Describes self-reported health outcomes attributed to recent use of LSD and other substances in a US survey, without reporting specific outcomes or effect sizes in the available text.
Synthesized
-
State of the evidence: MDMA Unclear
Describes self-reported health outcomes attributed to recent MDMA and other psychedelic use, but no specific outcomes or effect sizes are reported in the available text.
Synthesized
Comparable studies
Other cross-sectional and survey studies on ibogaine, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Examination of the Phenomenology of the Ibogaine Treatment Experience: Role of Altered States of Consciousness and Psychedelic Experiences. Individuals who used ibogaine in the past | 2017 | Retrospective survey | n = 27 |
| Not Losing Momentum: Cross-Sectional Insights into Ibogaine Clinical Trials. Clinical trials of ibogaine for substance use disorders | 2025 | Cross-sectional study | n = 9 |
Citations in the library
Cites 8
- MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nature Medicine October 1, 2023
- Psychedelic Drug Legislative Reform and Legalization in the US JAMA Psychiatry December 7, 2022
- Magnesium-ibogaine therapy in veterans with traumatic brain injuries. Nature Medicine February 1, 2024
- Safety of ibogaine administration in detoxification of opioid-dependent individuals: a descriptive open-label observational study. Addiction 2022
- Validation of the Swiss Psychedelic Side Effects Inventory: Standardized assessment of adverse effects in studies of psychedelics and MDMA. Journal of Affective Disorders November 15, 2024
and 3 more in the library